Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size

Khaled Ziada, MD

Status and phase: Terminated; Phase 4

Conditions: STEMI - ST Elevation Myocardial Infarction

Treatments: Drug: Cangrelor

Study type: Interventional

Funder types: Other

Identifiers

NCT03043274

16-0990-F6A

Details and patient eligibility

About

This study evaluates differences in the extent of myocardial necrosis noted by cardiac MRI in patients with ST-elevation myocardial infarction randomized to receive cangrelor during their percutaneous coronary intervention and compares them to patients randomized to not receive cangrelor.

Full description

Cangrelor is a direct-acting and reversible intravenously administered platelet inhibitor approved as an adjunct to percutaneous intervention (PCI) for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis. As it has a quick onset of action (2 minutes) compared to traditional oral platelet inhibitors, cangrelor is emerging as an important new option for use in patients undergoing percutaneous intervention who have not been treated with oral platelet inhibitors.

Furthermore, multiple studies have demonstrated that patients with ST-elevation myocardial infarction (STEMI) who undergo emergent PCI do not have optimal platelet inhibition even after administration of a loading dose of traditional oral platelet inhibitors. However, the clinical significance of complete platelet inhibition around the time of PCI is not fully understood.

The primary objective is to characterize the utility of immediate platelet inhibition with intravenous cangrelor in patients presenting with an acute STEMI by assessing the extent of infarct size (either enzymatically or by imaging). If the findings are favorable, this may suggest that immediate platelet inhibition is an important part of care in this patient population.

Enrollment: 23 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with an acute STEMI with the University of Kentucky as the institution of presentation with plans for PCI
• English-speaking

Exclusion criteria

• Pregnant patients
• Prisoners
• Patients who are unable to provide his/her own consent
• Patients with a prior history of myocardial infarction
• Patients who have received thrombolytics
• Patients on systemic anticoagulation
• Patients who are hemodynamically unstable with evidence of shock
• Patients who are mechanically intubated
• Patients with devices not MRI compatible
• Patients with chronic kidney disease, glomerular filtration rate less than 30
• Patients who are already on dual antiplatelet therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

23 participants in 2 patient groups

Cangrelor

Experimental group

Description:

Approximately 30 patients in this arm will receive standard STEMI care but will also receive standard dosing of cangrelor at the time of their PCI.

Treatment:

Drug: Cangrelor

No cangrelor

No Intervention group

Description:

Approximately 30 patients in this arm will receive standard STEMI but will not receive cangrelor at the time of their PCI.